Emerging Molecular Targets for the Treatment of Refractory Sarcoidosis

Valeyre, 2014, Sarcoidosis, Lancet Lond Engl., 383, 1155, 10.1016/S0140-6736(13)60680-7

Pereira, 2014, Clinical phenotypes in sarcoidosis, Curr Opin Pulm Med., 20, 496, 10.1097/MCP.0000000000000077

Newman, 2004, A case control etiologic study of sarcoidosis: environmental and occupational risk factors, Am J Respir Crit Care Med., 170, 1324, 10.1164/rccm.200402-249OC

Iannuzzi, 2007, Genetics of sarcoidosis, Semin Respir Crit Care Med., 28, 15, 10.1055/s-2007-970330

Zissel, 2010, Immunologic response of sarcoidosis, Semin Respir Crit Care Med., 31, 390, 10.1055/s-0030-1262208

Baughman, 2013, Established and experimental medical therapy of pulmonary sarcoidosis, Eur Respir J., 41, 1424, 10.1183/09031936.00060612

Baughman, 2011, A concise review of pulmonary sarcoidosis, Am J Respir Crit Care Med., 183, 573, 10.1164/rccm.201006-0865CI

Doty, 2003, Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen, Chest., 124, 2023, 10.1378/chest.124.5.2023

Chapelon-Abric, 2017, Cardiac sarcoidosis: diagnosis, therapeutic management and prognostic factors, Arch Cardiovasc Dis., 110, 456, 10.1016/j.acvd.2016.12.014

Joubert, 2017, Association of prognostic factors and immunosuppressive treatment with long-term outcomes in neurosarcoidosis, JAMA Neurol., 74, 1336, 10.1001/jamaneurol.2017.2492

Jamilloux, 2017, Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: a multicenter study of 132 patients, Semin Arthritis Rheum., 47, 288, 10.1016/j.semarthrit.2017.03.005

Maneiro, 2012, Efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish registry of biologics BIOBADASER and a systematic review, Semin Arthritis Rheum., 42, 89, 10.1016/j.semarthrit.2011.12.006

Marques, 1999, Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages, Am J Respir Crit Care Med., 159, 508, 10.1164/ajrccm.159.2.9804085

Baughman, 2006, Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement, Am J Respir Crit Care Med., 174, 795, 10.1164/rccm.200603-402OC

A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis2018 RossmanMD NewmanLS BaughmanRP TeirsteinA WeinbergerSE MillerW 18038919Sarcoidosis Vasc Diffuse Lung Dis.232006

Judson, 2008, Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial, Eur Respir J., 31, 1189, 10.1183/09031936.00051907

Pariser, 2013, A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis, J Am Acad Dermatol., 68, 765, 10.1016/j.jaad.2012.10.056

Vorselaars, 2013, Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis, Eur Respir J, 43, 602, 10.1183/09031936.00055213

Facco, 2011, Sarcoidosis is a Th1/Th17 multisystem disorder, Thorax., 66, 144, 10.1136/thx.2010.140319

Huang, 2013, Imbalance between Th17 and regulatory T-Cells in sarcoidosis, Int J Mol Sci., 14, 21463, 10.3390/ijms141121463

Kimura, 2010, IL-6: regulator of Treg/Th17 balance, Eur J Immunol., 40, 1830, 10.1002/eji.201040391

Sahashi, 1994, Significance of interleukin 6 in patients with sarcoidosis, Chest., 106, 156, 10.1378/chest.106.1.156

Girgis, 1995, Cytokines in the bronchoalveolar lavage fluid of patients with active pulmonary sarcoidosis, Am J Respir Crit Care Med., 152, 71, 10.1164/ajrccm.152.1.7599865

Takizawa, 1997, Increased IL-6 and IL-8 in bronchoalveolar lavage fluids (BALF) from patients with sarcoidosis: correlation with the clinical parameters, Clin Exp Immunol., 107, 175, 10.1046/j.1365-2249.1997.d01-905.x

Chazal, 2019, The cerebrospinal fluid CD4/CD8 ratio and interleukin-6 and−10 levels in neurosarcoidosis: a multicenter, pragmatic, comparative study, Eur J Neurol., 26, 1274, 10.1111/ene.13975

Bihl, 2006, Progressive pulmonary sarcoidosis–a fibroproliferative process potentially triggered by EGR-1 and IL-6, Sarcoidosis Vasc Diffuse Lung Dis., 23, 38, 10.1183/09031936.00051907

Grutters, 2003, Analysis of IL6 and IL1A gene polymorphisms in UK and Dutch patients with sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis., 20, 20

Chen, 2010, Serum amyloid a regulates granulomatous inflammation in sarcoidosis through toll-like receptor-2, Am J Respir Crit Care Med., 181, 360, 10.1164/rccm.200905-0696OC

Awano, 2012, Mixed-type multicentric Castleman's disease developing during a 17-year follow-up of sarcoidosis, Intern Med Tokyo Jpn., 51, 3061, 10.2169/internalmedicine.51.8120

Semiz, 2019, Coexistence of sarcoidosis and adult onset Still disease, Reumatol Clin., 15, e18, 10.1016/j.reuma.2017.04.004

Sharp, 2019, Tocilizumab in sarcoidosis patients failing steroid sparing therapies and anti-TNF agents, Respir Med X., 1, 100004, 10.1016/j.yrmex.2019.100004

Yoshimura, 2009, Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis, Rheumatol Oxf Engl., 48, 347, 10.1093/rheumatology/ken489

Silpa-Archa, 2016, Outcome of tocilizumab treatment in refractory ocular inflammatory diseases, Acta Ophthalmol., 94, e400, 10.1111/aos.13015

Vegas-Revenga, 2019, Anti-IL6-receptor tocilizumab in refractory and noninfectious uveitic cystoid macular edema: multicenter study of 25 patients, Am J Ophthalmol., 200, 85, 10.1016/j.ajo.2018.12.019

Nutz, 2013, Sarcoidosis induced by tocilizumab: a paradoxical event?, J Rheumatol., 40, 1773, 10.3899/jrheum.130278

Bustamente, 2017, Sarcoidosis and tocilizumab: is there a link?, Clin Exp Rheumatol., 35, 716

Shono, 2018, Cutaneous sarcoidosis in a patient with rheumatoid arthritis receiving tocilizumab, J Dermatol., 45, e217, 10.1111/1346-8138.14268

Del Giorno, 2019, New-onset cutaneous sarcoidosis under tocilizumab treatment for giant cell arteritis: a quasi-paradoxical adverse drug reaction. Case report and literature review, Ther Adv Musculoskelet Dis., 11, 1759720X19841796, 10.1177/1759720X19841796

Yimin, 2006, A regulatory effect of the balance between TNF-alpha and IL-6 in the granulomatous and inflammatory response to Rhodococcus aurantiacus infection in mice, J Immunol., 177, 642, 10.4049/jimmunol.177.1.642

Yimin, 2003, Up-regulation of granulomatous inflammation in interleukin-6 knockout mice infected with Rhodococcus aurantiacus, Immunology, 110, 501, 10.1111/j.1365-2567.2003.01762.x

Rolfe, 1993, Interleukin-1 receptor antagonist expression in sarcoidosis, Am Rev Respir Dis., 148, 1378, 10.1164/ajrccm/148.5.1378

Mikuniya, 1997, Quantitative evaluation of the IL-1 beta and IL-1 receptor antagonist obtained from BALF macrophages in patients with interstitial lung diseases, Sarcoidosis Vasc Diffuse Lung Dis., 14, 39

Mikuniya, 2000, Significance of the interleukin-1 receptor antagonist/interleukin-1 beta ratio as a prognostic factor in patients with pulmonary sarcoidosis, Respir Int Rev Thorac Dis., 67, 389, 10.1159/000029536

Cvetkovic, 2002, Anakinra, BioDrugs., 16, 303, 10.2165/00063030-200216040-00005

Kalliolias, 2008, The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis, Expert Opin Investig Drugs., 17, 349, 10.1517/13543784.17.3.349

Sacre, 2013, Sarcoid-like granulomatosis in a patient treated by interleukin-1 receptor antagonist for TNF-receptor-associated periodic syndrome, Rheumatol Oxf Engl., 52, 1338, 10.1093/rheumatology/kes377

Friedman, 2018, Drug-induced sarcoidosis in a patient treated with an interleukin-1 receptor antagonist for hidradenitis suppurativa, JAAD Case Rep., 4, 543, 10.1016/j.jdcr.2018.03.007

Crouser, 2018, Role of imbalance between Th17 and regulatory T-cells in sarcoidosis, Curr Opin Pulm Med., 24, 521, 10.1097/MCP.0000000000000498

Curtis, 2009, Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens, Immunology., 126, 177, 10.1111/j.1365-2567.2008.03017.x

Ten Berge, 2012, Increased IL-17A expression in granulomas and in circulating memory T cells in sarcoidosis, Rheumatol Oxf Engl., 51, 37, 10.1093/rheumatology/ker316

Ostadkarampour, 2014, Higher levels of interleukin IL-17 and antigen-specific IL-17 responses in pulmonary sarcoidosis patients with Löfgren's syndrome, Clin Exp Immunol., 178, 342, 10.1111/cei.12403

Talreja, 2019, HIF-1α regulates IL-1β and IL-17 in sarcoidosis, eLife., 8, e44519, 10.7554/eLife.44519

Wu, 2014, Overexpression of IL-17RC associated with ocular sarcoidosis, J Transl Med., 12, 152, 10.1186/1479-5876-12-152

Orrell, 2018, Inflammatory bowel disease events after exposure to interleukin 17 inhibitors secukinumab and ixekizumab: postmarketing analysis from the RADAR (“research on adverse drug events and reports”) program, J Am Acad Dermatol., 79, 777, 10.1016/j.jaad.2018.06.024

Toussirot, 2019, Safety of the use of anti-IL17A treatment in a patient with certolizumab-induced sarcoidosis, Clin Exp Rheumatol., 37, 344

Eichhoff, 2020, Management with secukinumab of tumour necrosis factor inhibitor-induced pulmonary sarcoidosis-like reaction in a patient with psoriasis, Clin Exp Dermatol., 45, 455, 10.1111/ced.14101

Nyckowski, 2017, Sarcoidosis developing during secukinumab therapy: case report, SKIN J Cutan Med., 1, 95, 10.25251/skin.1.2.7

Sambharia, 2018, Worsening of pulmonary sarcoidosis induced by ixekizumab: a rare paradox, Chest., 154, 898A, 10.1016/j.chest.2018.08.808

Letko, 2015, Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy, Ophthalmology., 122, 939, 10.1016/j.ophtha.2014.12.033

Trinchieri, 1993, Interleukin-12 and its role in the generation of TH1 cells, Immunol Today., 14, 335, 10.1016/0167-5699(93)90230-I

Mroz, 2008, Increased levels of interleukin-12 and interleukin-18 in bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis, J Physiol Pharmacol., 59, 507

Taha, 1999, Increased expression of IL-12 receptor mRNA in active pulmonary tuberculosis and sarcoidosis, Am J Respir Crit Care Med., 160, 1119, 10.1164/ajrccm.160.4.9807120

Shigehara, 2000, Enhanced mRNA expression of Th1 cytokines and IL-12 in active pulmonary sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis., 17, 151

Shigehara, 2001, IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs, J Immunol., 166, 642, 10.4049/jimmunol.166.1.642

Shigehara, 2003, Increased circulating interleukin-12 (IL-12) p40 in pulmonary sarcoidosis, Clin Exp Immunol., 132, 152, 10.1046/j.1365-2249.2003.02105.x

Parham, 2002, A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R, J Immunol., 168, 5699, 10.4049/jimmunol.168.11.5699

Judson, 2012, Molecular profiling and gene expression analysis in cutaneous sarcoidosis: the role of interleukin-12, interleukin-23, and the T-helper 17 pathway, J Am Acad Dermatol., 66, 901, 10.1016/j.jaad.2011.06.017

Kim, 2011, Association of interleukin 23 receptor gene with sarcoidosis, Dis Markers., 31, 17, 10.1155/2011/185106

Sands, 2019, Ustekinumab as induction and maintenance therapy for ulcerative colitis, N Engl J Med, 382, 91, 10.1056/NEJMoa1900750

Judson, 2014, Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis, Eur Respir J., 44, 1296, 10.1183/09031936.00000914

Powell, 2015, Acute systemic sarcoidosis complicating ustekinumab therapy for chronic plaque psoriasis, Br J Dermatol., 172, 834, 10.1111/bjd.13365

Gad, 2019, Sarcoid- like phenomenon - ustekinumab induced granulomatous reaction mimicking diffuse metastatic disease: a case report and review of the literature, J Med Case Rep., 13, 257, 10.1186/s13256-019-2137-1

Kobak, 2020, Ustekinumab-induced sarcoidosis in a patient with psoriatic arthritis, Curr Drug Saf, 15, 163, 10.2174/1574886315666200316113312

Thomas, 2020, Poor control of sarcoidosis-related panuveitis with an antibody to IL-23, Ocul Immunol Inflamm., 28, 491, 10.1080/09273948.2019.1569245

Hattori, 2005, Cytotoxic T-lymphocyte antigen 4 gene polymorphisms in sarcoidosis patients, Sarcoidosis Vasc Diffuse Lung Dis., 22, 27

Dubois, 2009, Abatacept, Br J Clin Pharmacol., 68, 480, 10.1111/j.1365-2125.2009.03502.x

Iannuzzi, 2007, Sarcoidosis, N Engl J Med., 357, 2153, 10.1056/NEJMra071714

Lee, 2011, Disturbed homeostasis and multiple signaling defects in the peripheral blood B-cell compartment of patients with severe chronic sarcoidosis, Clin Vaccine Immunol CVI., 18, 1306, 10.1128/CVI.05118-11

Fazel, 1992, B lymphocyte accumulations in human pulmonary sarcoidosis, Thorax., 47, 964, 10.1136/thx.47.11.964

Saussine, 2012, Active chronic sarcoidosis is characterized by increased transitional blood B cells, increased IL-10-producing regulatory B cells and high BAFF levels, PLoS ONE., 7, e43588, 10.1371/journal.pone.0043588

Beccastrini, 2013, Successful treatment of ocular sarcoidosis with rituximab, Ocul Immunol Inflamm., 21, 244, 10.3109/09273948.2012.762982

Cinetto, 2015, Rituximab in refractory sarcoidosis: a single centre experience, Clin Mol Allergy., 13, 19, 10.1186/s12948-015-0025-9

Gottenberg, 2005, Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases, Ann Rheum Dis., 64, 913, 10.1136/ard.2004.029694

Zella, 2018, Successful therapy with rituximab in three patients with probable neurosarcoidosis, Ther Adv Neurol Disord., 11, 1756286418805732, 10.1177/1756286418805732

Bomprezzi, 2010, A case of neurosarcoidosis successfully treated with rituximab, Neurology., 75, 568, 10.1212/WNL.0b013e3181ec7ff9

Sawaya, 2013, Sarcoidosis associated with neuromyelitis optica, J Clin Neurosci., 20, 1156, 10.1016/j.jocn.2012.09.030

Lower, 2012, Rituximab for refractory granulomatous eye disease, Clin Ophthalmol., 6, 1613, 10.2147/OPTH.S35521

Dalia, 2018, A rare case of sarcoidosis presenting with cutaneous medium-vessel granulomatous vasculitis treated with rituximab, J Clin Rheumatol, 5

Earle, 2019, Novel use of rituximab in treatment of refractory neurosarcoidosis in an 11-year-old girl, J Clin Rheumatol., 25, e101, 10.1097/RHU.0000000000000900

Krause, 2016, Successful use of rituximab in refractory cardiac sarcoidosis, Rheumatol Oxf Engl., 55, 189, 10.1093/rheumatology/kev309

Sweiss, 2014, Rituximab in the treatment of refractory pulmonary sarcoidosis, Eur Respir J., 43, 1525, 10.1183/09031936.00224513

Broos, 2016, T-cell immunology in sarcoidosis: disruption of a delicate balance between helper and regulatory T-cells, Curr Opin Pulm Med., 22, 476, 10.1097/MCP.0000000000000303

Ramstein, 2016, IFN-γ-Producing T-Helper 17.1 cells are increased in sarcoidosis and are more prevalent than T-helper type 1 cells, Am J Respir Crit Care Med., 193, 1281, 10.1164/rccm.201507-1499OC

Rosenbaum, 2009, Hypothesis: sarcoidosis is a STAT1-mediated disease, Clin Immunol., 132, 174, 10.1016/j.clim.2009.04.010

Zhou, 2017, Identification of Jak-STAT signaling involvement in sarcoidosis severity via a novel microRNA-regulated peripheral blood mononuclear cell gene signature, Sci Rep., 7, 4237, 10.1038/s41598-017-04109-6

Zhou, 2012, Peripheral blood gene expression as a novel genomic biomarker in complicated sarcoidosis, PLoS ONE., 7, e44818, 10.1371/journal.pone.0044818

Li, 2017, Bioinformatics analysis of gene expression profile data to screen key genes involved in pulmonary sarcoidosis, Gene., 596, 98, 10.1016/j.gene.2016.09.037

Rosenbaum, 2010, The expression of STAT-1 and phosphorylated STAT-1 in conjunctival granulomas, Ocul Immunol Inflamm., 18, 261, 10.3109/09273941003797934

Rotenberg, 2018, Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia, Eur Respir J., 52, 1801482, 10.1183/13993003.01482-2018

Levraut, 2019, Refractory sarcoidosis-like systemic granulomatosis responding to ruxolitinib, Ann Rheum Dis., 78, 1606, 10.1136/annrheumdis-2019-215387

Wei, 2019, Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera, JAAD Case Rep., 5, 360, 10.1016/j.jdcr.2019.02.006

Damsky, 2018, Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis, N Engl J Med., 379, 2540, 10.1056/NEJMoa1805958

Damsky, 2020, Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare, J Am Acad Dermatol., 82, 612, 10.1016/j.jaad.2019.05.098

Damsky, 2020, Treatment of multiorgan sarcoidosis with tofacitinib, ACR Open Rheumatol., 2, 106, 10.1002/acr2.11112

Scheinberg, 2020, Steroid-resistant sarcoidosis treated with baricitinib, Ann Rheum Dis, 79, 1259, 10.1136/annrheumdis-2020-217271

Keating, 2017, Apremilast: a review in psoriasis and psoriatic arthritis, Drugs., 77, 459, 10.1007/s40265-017-0709-1

Baughman, 2012, Efficacy and safety of apremilast in chronic cutaneous sarcoidosis, Arch Dermatol., 148, 262, 10.1001/archdermatol.2011.301